LUNA 3 Trial: BTK Inhibition for ITP Management
Rilzabrutinib Demonstrates Sustained Benefit in Chronic Immune Thrombocytopenia
Table of Contents
Updated October 10, 2025
Notable Platelet Response Achieved in Global Trial
A global Phase 3 trial, involving participants from 26 countries, has shown rilzabrutinib to be effective in treating chronic immune thrombocytopenia (ITP).Teh randomized, double-blind, placebo-controlled study utilized a 2:1 randomization favoring rilzabrutinib. During the initial 12-week period, 64% of patients receiving rilzabrutinib experienced a positive platelet response.
The study’s primary endpoint - durable platelet response – was met by 23% of participants treated with rilzabrutinib, compared to 0% in the placebo group. This indicates a clinically significant adn sustained improvement for individuals living with ITP.
Improved Patient Outcomes beyond Platelet Counts
Secondary endpoints consistently favored rilzabrutinib across several key measures of patient well-being. Patients receiving rilzabrutinib maintained a platelet response for an average of 6.46 weeks longer and those who responded to the treatment sustained that response for 8.8 weeks longer than those receiving placebo.
The time to initial platelet response was rapid in rilzabrutinib responders, averaging 15 days, compared to 36 days for all treated participants. Notably, individuals in the placebo group did not achieve a response. The need for rescue medication – a crucial indicator of treatment effectiveness – was reduced by 52%, with 33% of rilzabrutinib-treated patients requiring rescue therapy versus 58% in the placebo group. The median time to needing rescue medication was not reached in the rilzabrutinib arm, compared to 56 days for the placebo group.
Enhanced Quality of Life Reported by patients
The LUNA 3 trial was the first prospective ITP study to comprehensively evaluate patient-reported quality-of-life metrics across ten different domains. Significant improvements in all quality-of-life measures were observed in patients receiving rilzabrutinib compared to placebo, with particularly noticeable gains in reducing fatigue and bleeding scores as early as week 5.
This combination of improved platelet counts *and* enhanced patient-reported outcomes addresses a historical challenge in ITP treatment, where increases in platelet levels haven’t always translated to better daily functioning.The observed quality-of-life benefits likely stem from rilzabrutinib’s ability to reduce the underlying inflammation associated with ITP,providing patients with improvements that extend beyond laboratory results.